Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer

NCT00845884 | Unknown Phase 1

• 1 other identifier: AVDCF-2008
• Study Type: interventional
• Target: 49
• Locations: 1 country
• Sites: 1

Brief Summary

In spite of multiple attempts to improve the efficacy of first-line chemotherapy in advanced gastric cancer, the progress that has been achieved so far is rather limited, and many investigators are exploring newer regimens.A combination of decetaxel (Taxotere) with Cisplatin and 5-fluorouracil (5FU) is considered one of the most effective regimens in this disease. However, it is associated with significant toxicity which avoided its general adaptation by the medical community. The current study is exploring a newer way to administer these three drugs, hopefully making the regimen more comfortable, less toxic and maybe even more effective. We will do this by changing the dose and timing of Taxotere and Cisplating, by replacing protracted infusion of 5FU with tablets of Capecitabine (Xeloda) and by adding the anti-angiogenic drug, Bevacizumab (Avastin), which had shown encouraging results in this disease.

Conditions

Advanced Gastric Cancer

Keywords

Gastric; Cancer; Advanced; Docetaxel; Cisplatin; Capecitabine; Bevacizumab

Outcome Measures

Primary Outcomes (1)

• response rate

  2/2009-12/2012

Secondary Outcomes (1)

• Safety, PFS, overall survival

  2/2009-12/2012

Study Arms (1)

AVDCF

EXPERIMENTAL

Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab

Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab

Interventions

Docetaxel, Cisplatin, Capecitabine, Bevacizumab DRUG

* Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days. * Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days. * Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days. * Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days.

Also known as: Taxotere (Docetaxel), Cisplatin, Xeloda (Capecitabine), Avastin (Bevacizumab

AVDCF

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients above 18 years of age at the time of enrollment.
• Histologically confirmed previously untreated metastatic or unresectable adenocarcinoma of the stomach.
• Patients must have at least one measurable lesion (measuring \>10mm in standard CT or \>5mm in spiral CT).
• Adequate organ function.
• Life expectancy of at least three months.
• Patients must have an ECOG Performance Status of 0 or 1.
• Signed written informed consent to participate in the study.

You may not qualify if:

• Participation in an investigational trial within 30 days of the screening visit.
• Known allergy or any other adverse reaction to any of the study drugs or to any related compound.
• Prior anti-angiogenic treatment, chemotherapy or radiotherapy for advanced disease. Patients will be eligible if they had received adjuvant chemotherapy or radiotherapy more than 12 months prior to enrollment.
• Prior treatment with drugs included in the investigational regimen. Prior use of 5-fluorouracil in the adjuvant setting is allowed.
• Significant bleeding by the primary tumor (in unoperated patients).
• Clinically significant (i.e. active) cardiovascular disease. This includes, but is not limited to, the following examples:
• Cerebrovascular accidents (up to 6 months prior to randomization)
• Myocardial infarction (up to 1 year prior to randomization).
• Uncontrolled hypertension (above 150/100 mmHg) while receiving chronic medication
• Unstable angina
• New York Heart Association (NYHA) Grade II or greater congestive heart failure.
• Serious cardiac arrhythmia requiring medication.
• Clinically significant ECG findings. Patients who suffer from serious cardiac arrhythmia requiring medication can enter the study only if they are considered to be in a stable condition regarding both the arrhythmia and their medication. Patients with pacemakers are allowed to enter the study only if they are considered as being in a stable condition. In case of doubt, the investigator should obtain a consultation with a local cardiologist.
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, not fully healed wounds, or anticipation of the need for major surgical procedure during the course of the study.
• Severe co-morbid conditions including uncontrolled diabetes or hypertension, cerebral vascular disease or uncontrolled infection.

Sponsors & Collaborators

• Rabin Medical Center: lead

Study Sites (1)

Davidoff Cancer Center, Rabin Medical Center

Petah Tikva, 49100, Israel

Location

Related Publications (1)

• Brenner B, Sarfaty M, Purim O, Kundel Y, Amit L, Abramovich A, Sadeh Gonik U, Idelevich E, Gordon N, Medalia G, Sulkes A. A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer. PLoS One. 2016 Jul 8;11(7):e0157548. doi: 10.1371/journal.pone.0157548. eCollection 2016.

  PMID: 27390847 DERIVED

MeSH Terms

Conditions

Neoplasms

Interventions

Docetaxel; Cisplatin; Capecitabine; Bevacizumab

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Fluorouracil; Uracil; Pyrimidinones; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Baruch Brenner, MD

  Davidoff Cancer Center, Rabin Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: February 16, 2009
• First Posted: February 18, 2009
• Study Start: February 1, 2009
• Primary Completion: December 1, 2012
• Study Completion: December 1, 2012
• Last Updated: February 18, 2009

Record last verified: 2009-02

Locations

IL (1)